Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285538 | 0.89 | KMT2A (0.43) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL471729 | 0.88 | ALDH1A1 (0.50) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL6287265 | 0.88 | KMT2A (0.43) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL18711241 | 0.87 | KMT2A (0.48) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL22030392 | 0.86 | ALDH1A1 (0.49) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL6286733 | 0.86 | KMT2A (0.42) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL6289546 | 0.84 | KMT2A (0.46) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL6284231 | 0.84 | KMT2A (0.40) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL6289602 | 0.82 | KMT2A (0.39) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL24530272 | 0.82 | KMT2A (0.47) | KMT2ARAB9AALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3666274-A1 | CARBOXAMIDE DERIVATIVES AND USE THEREOF | Purdue Pharma LP (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3221306-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-11-13 | — | — | EP | disclosed |
| WO-2019160882-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20170096421-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2017-04-06 | — | — | US | disclosed |
| US-9493449-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2016081679-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | WO | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6916854-B2 | Heat and/or light curable films or coatings comprising polyurethanes or polyureaurethane copolymers having storage stability, used as automobile paints | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20040097642-A1 | Unsaturated compounds containing carbamate terminal groups or urea terminal groups | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | ADORA3, ADORA1, ADORA2A | KMT2A 2686/4885RAB9A 2270/4885ALDH1A1 265/4885 |
| US-20170096421-A1 | Carboxamide Derivatives and Use Thereof | TRPV1, CACNA1A, SCN10A | KMT2A 1142/4885RAB9A 1769/4885ALDH1A1 1621/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | KMT2A 939/4885RAB9A 5/4885ALDH1A1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.